OncLive TV

Jacob Moyer, BS, discusses early, real-world efficacy and safety data with nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer.

Alfred L. Garfall, MD, describes the inclusion criteria for a phase 2 study evaluating ide-cel as first-line maintenance in multiple myeloma.

Catherine C. Coombs, MD, discusses the need to establish a standardized definition of high-risk CLL.

Marwan Fakih, MD, discusses the advancement of botensilimab/balstilimab–based combination therapies in microsatellite-stable colorectal cancer.

Alberto Montero, MD, MBA, CPHQ, explains the rationale for evaluating zanidatamab plus evorpacept in HER2-expressing metastatic breast cancer.

Elizabeth Lee, MD, discusses the efficacy of rinatabart sesutecan in patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Taliya Lantsman, MD, discusses real-world safety and efficacy data with dostarlimab plus chemotherapy in patients with advanced endometrial cancer.

Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.

Melanie A. Sheen, MD, discusses a study aimed at determining differences in breast composition and assess racial disparities in access to and utilization of genetic counseling.

Amanda Herrmann, MD, discusses findings from the TIME-TOX Lung study, which retrospectively assessed the time toxicity associated with lung cancer clinical trials.

Raajit Rampal, MD, discusses the variety of agents in phase 3 trials for the treatment of patients with myelofibrosis.

Shannon Westin, MD, MPH, FACOG, discusses the efficacy of durvalumab plus chemotherapy and olaparib in pMMR recurrent endometrial cancer.

Jordyn Silverstein, MD, discusses the efficacy of abemaciclib plus hormonal therapy in recurrent ovarian cancer or endometroid endometrial cancer.

Rachel N. Grisham, MD, discusses the efficacy of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.

Toon Van Gorp, MD, PhD, discusses the efficacy of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian cancer after 30.5 months of follow-up.

Joshua Richter, MD, discusses the evolution of multiple myeloma treatment in recognition of Myeloma Awareness Month 2025.

Guenther Koehne, MD, discusses the roles of ASCT, CAR T-cell therapy, and bispecific antibodies in the treatment of patients with multiple myeloma.

Grzegorz S. Nowakowsi, MD, discusses the unique mechanism of action of brentuximab vedotin plus lenalidomide and rituximab in ​relapsed/refractory LBCL.

Bradley McGregor, MD, discusses the rationale for analyzing efficacy and safety exposure response to tivozanib in patients with renal cell carcinoma.

Tycel J. Phillips, MD, MPH, discusses the need for more large, randomized clinical trials enrolling patients with high-risk MCL.

Katherine L. Nathanson, MD, discusses the impact of reversion mutations on resistance to PARP inhibitors across various DNA damage repair genes.

Daniel J. DeAngelo, MD, PhD, discusses the clinical implications of findings from the PATHFINDER trial of avapritinib in advanced ​​systemic mastocytosis.

Julie M. Vose, MD, MBA, highlights the safety of epcoritamab in patients with relapsed/refractory large B-cell lymphoma.

Rami Komrokji, MD, discusses how consensus guidelines could address unanswered questions regarding the management of high-risk MDS.

Matthew Wagar, MD, discusses how the management of advanced and recurrent endometrial cancer has evolved in recent years.

Martin Dreyling, MD, discusses the rationale for evaluating the addtion of ibrutinib to chemoimmunotherapy and ASCT in mantle cell lymphoma.

Kelly E. McCann, MD, PhD, discusses several targeted approaches under investigation in HER2-positive breast cancer.

Coy Heldermon, MD, PhD, discusses a phase 1/2 trial design evaluating pharmacokinetics and safety of epidiferphane given with taxane chemotherapy in breast cancer.

Kathleen N. Moore, MD, MS, discusses novel antibody-drug conjugates currently in development for patients with FRα-expressing ovarian cancer.

Ritu Salani, MD, MBA, discusses considerations in clinical trial design and the evolving role of HER2-targeted ADCs in gynecologic malignancies.